Antagonisty androgénov.Abirateron acetát (INN, USAN, BAN, JAN) (značky Zytiga, Abirate, Abretone, Abirapro) je steroidný antiandrogén, konkrétne inhibítor syntézy androgénov, používa sa v kombinácii s metastatickým karcinómom prostaty rezistentným na kastráciu (predtým nazývaný hormonálne rezistentný alebo hormonálne refraktérny karcinóm prostaty) - t.j., rakovina prostaty nereagujúca na androgénnu depriváciu alebo liečbu antagonistami androgénneho receptora. Je to prekurzor účinnej látky abirateron, and is marketed by Janssen Biotech under the trade name Zytiga. Okrem toho, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.
Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.
